For a long time, male contraceptive options have been limited to condoms and vasectomy—the former carrying a risk of failure, and the latter being difficult to reverse. In recent years, scientists have been working to develop reversible male contraceptive methods, with the goal of temporarily halting sperm production without affecting sexual function or long-term fertility. Most of this research is in the clinical trial stage, but it has already shown promise.
Hormonal contraception is one of the mainstream directions. The principle involves supplementing exogenous testosterone and progestin to suppress the pituitary gland's secretion of gonadotropins, thereby shutting down the sperm production line within the testes. Studies show that regular injections or implanted sustained-release formulations can bring most men to a state of azoospermia or severe oligospermia within weeks, with sperm counts returning to normal within months after discontinuation. However, some participants experience side effects such as weight gain and mood swings, and there is individual variation in effectiveness.
Non-hormonal methods target specific proteins or genes involved in the sperm production process. For example, a compound called "YCT529" can block the metabolic pathway of vitamin A in the testes, and vitamin A is critical for sperm development. In animal experiments, mice given the drug orally lost fertility within weeks and recovered after discontinuation. Another strategy involves the use of "spermatogenesis inhibitors," which directly interfere with the division and maturation of sperm cells, but human trials are still in the early stages.
In addition, ultrasound technology is also being explored as a non-invasive option. High-frequency ultrasound can heat testicular tissue, temporarily destroying spermatogonial cells to achieve a contraceptive effect. Preliminary studies show that a single 15-minute treatment can reduce sperm counts for several weeks without affecting testosterone secretion. However, optimal parameters and long-term safety still require more data for validation.
These new methods are still some distance from market availability, with the main challenges being ensuring near-100% contraceptive efficacy, manageable side effects, and predictable reversal time. Currently, hormonal products are progressing the fastest, but non-hormonal approaches are highly anticipated due to fewer side effects. For men in stable relationships who wish to share contraceptive responsibility, options such as injections, oral medications, or localized treatments may be available in the future, but for now, reliance on existing options remains necessary.
This article is general science information and does not constitute individualized medical advice. For specific diagnosis and treatment, please consult a professional medical institution.
Author LinkedIVF TeamPublished 2026-08-03
This article used AI assistance; LinkedIVF has not recorded an editorial review for this item. It is not medical advice.
This content is for informational purposes only and does not constitute medical advice. Please consult a licensed physician. Content guidelines & editorial policy
New Breakthrough in Male Reversible Contraception: How to Stop Sperm Production?
For a long time, male contraceptive options have been limited to condoms and vasectomy—the former carrying a risk of failure, and the latter being difficult to reverse. In recent years, scientists have been working to develop reversible male contraceptive methods, with the goal of temporarily halting sperm production without affecting sexual function or long-term fertility. Most of this research is in the clinical trial stage, but it has already shown promise.
Hormonal contraception is one of the mainstream directions. The principle involves supplementing exogenous testosterone and progestin to suppress the pituitary gland's secretion of gonadotropins, thereby shutting down the sperm production line within the testes. Studies show that regular injections or implanted sustained-release formulations can bring most men to a state of azoospermia or severe oligospermia within weeks, with sperm counts returning to normal within months after discontinuation. However, some participants experience side effects such as weight gain and mood swings, and there is individual variation in effectiveness.
Non-hormonal methods target specific proteins or genes involved in the sperm production process. For example, a compound called "YCT529" can block the metabolic pathway of vitamin A in the testes, and vitamin A is critical for sperm development. In animal experiments, mice given the drug orally lost fertility within weeks and recovered after discontinuation. Another strategy involves the use of "spermatogenesis inhibitors," which directly interfere with the division and maturation of sperm cells, but human trials are still in the early stages.
In addition, ultrasound technology is also being explored as a non-invasive option. High-frequency ultrasound can heat testicular tissue, temporarily destroying spermatogonial cells to achieve a contraceptive effect. Preliminary studies show that a single 15-minute treatment can reduce sperm counts for several weeks without affecting testosterone secretion. However, optimal parameters and long-term safety still require more data for validation.
These new methods are still some distance from market availability, with the main challenges being ensuring near-100% contraceptive efficacy, manageable side effects, and predictable reversal time. Currently, hormonal products are progressing the fastest, but non-hormonal approaches are highly anticipated due to fewer side effects. For men in stable relationships who wish to share contraceptive responsibility, options such as injections, oral medications, or localized treatments may be available in the future, but for now, reliance on existing options remains necessary.
This article is general science information and does not constitute individualized medical advice. For specific diagnosis and treatment, please consult a professional medical institution.